Treating Burkitt Lymphoma in Adults

@article{Casulo2015TreatingBL,
  title={Treating Burkitt Lymphoma in Adults},
  author={Carla Casulo and Jonathan W. Friedberg},
  journal={Current Hematologic Malignancy Reports},
  year={2015},
  volume={10},
  pages={266-271}
}
Burkitt lymphoma is an uncommon form of aggressive lymphoma affecting approximately 1200 patients per year in the USA. It is characterized by a translocation involving the MYC oncogene. Three subtypes of Burkitt lymphoma are recognized: the endemic form, occurring primarily in Africa and associated with the Epstein-Barr virus (EBV); the sporadic form, representing less than 3 % of all non-Hodgkin lymphomas (NHL); and the immunodeficiency-associated form, occurring primarily in HIV-infected… 
Burkitt lymphoma- a rare but challenging lymphoma.
Management of adults with Burkitt lymphoma.
TLDR
The infusional regimen of dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and regular- or double-dose rituximab (DA-EPOCH-R or -RR) is less toxic than standard BL regimens, yet maintains high rates of cure across a diverse range of patients, including those with disseminated disease, advanced age, and HIV infection.
Burkitt and Burkitt-Like Lymphomas: a Systematic Review
TLDR
Rituximab-based short-course dose-intensive chemotherapy is the standard of care of Burkitt’s lymphoma even in the immunodeficiency-related form.
Oral Burkitt's lymphoma associated with human immunodeficiency virus
TLDR
Burkitt's lymphoma is an aggressive neoplasia with a rapidly progressing clinical course, therefore, differential diagnosis from other benign oral diseases is of great importance.
Intraoral EBV-positive sporadic Burkitt lymphoma in an elderly patient with bilateral presentation
TLDR
A case of a 63-year-old male presenting intraoral bilateral mandibular swelling, subjacent to fixed dental prosthesis, with one month of duration, and died after a week when an abdominal tumor was detected was described.
How I treat double-hit lymphoma.
TLDR
The approach to the evaluation and treatment of double-hit lymphoma is reviewed, with an eye toward future clinical trials incorporating rational targeted agents into the therapeutic armamentarium.
Treatment outcomes of adult Burkitt lymphoma: results with a modified LMB protocol in Brazil and feasibility of outpatient administration
TLDR
It is concluded that an adapted LMB protocol is safe and feasible in Brazil and should be extended to all adults with sporadic Burkitt lymphoma.
Rituximab and Immune Molecule Modulation in Burkitt’s Lymphoma Cell Lines
TLDR
Downregulation of HLA-I could contribute to an immune escape mechanism in Burkitt’s lymphoma, and the immune inhibitor PD-L1 was decreased on EBV-positive COX and Raji, but increased onEBV-negative Ramos and Bjab.
A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study
TLDR
The new prognostic model could be used to develop risk-adapted treatment approaches for adult sporadic BL and establish a novel, clinically applicable prognostic index for adult patients with sporadic BL.
Recent advances in treating extra-ocular lymphomas
TLDR
This review provides an overview of the available treatment modalities for ocular adnexal lymphoma, including novel treatment approaches and recent advances, and suggests that the treatment should be centralized in centers in each country and placed in a small number of experienced hands.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Burkitt's lymphoma in Africa, a review of the epidemiology and etiology.
TLDR
Evidence for a causal relationship between EBV and BL in the endemic form is fairly strong, and EBV may play a role in the pathogenesis of BL by deregulation of the oncogene c-MYC by chromosomal translocation.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
TLDR
High-throughput RNA sequencing and RNA interference screening is used to discover essential regulatory pathways in Burkitt's lymphoma that cooperate with MYC, the defining oncogene of this cancer.
Molecular diagnosis of Burkitt's lymphoma.
TLDR
Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma and the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
A Multifactorial Role for P. falciparum Malaria in Endemic Burkitt's Lymphoma Pathogenesis
TLDR
P. falciparum targets GC B cells via multiple pathways to increase the risk of endemic Burkitt's lymphoma and it is proposed that these activities combine synergistically to dramatically increase the incidence of eBL in individuals infected with malaria.
The Distinction between Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma with c-myc Rearrangement
TLDR
It is concluded that a growth fraction of nearly 100%, as well as a monotonous proliferation of medium-sized cells and c-mycR, should be of value in the diagnosis of BL, which is probably different from c- mycR DLBCL.
Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.
TLDR
This retrospective study involved 65 adult patients with small noncleaved cell lymphoma or ALL3 treated with the LMB protocols and found that seven of 12 patients with initial CNS disease are alive with a median survival of 56 months.
Low-intensity therapy in adults with Burkitt's lymphoma.
TLDR
In this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma.
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
TLDR
It is concluded that modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma; selected patients over age 40 now have highly favorable outcomes; and future studies should include formal analysis of this subgroup of patients.
The genetic landscape of mutations in Burkitt lymphoma
TLDR
This work elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a new tumor suppressor gene and shows experimentally that ID3 mutations promote cell cycle progression and proliferation.
Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males.
TLDR
There is a definite trend for the development of aggressive non-Hodgkin's lymphomas with unusual sites of extranodal involvement in immunocompromised homosexual males, with the potential for good tolerance to combination chemotherapy and improved survival in the subgroup without severe concomitant opportunistic infections.
...
...